Influenza A Subtype H5N1 Infection
Conditions
Keywords
Influenza, Vaccine, Pandemic, Avian influenza, Adenovirus strain 5, Vectored vaccine, Intranasal, Tissue-culture derived, Non-replicating
Brief summary
The purpose of this study is to test the recombinant vaccine for safety and immunogenicity in healthy adults volunteers. Single dose, intranasally administered vaccine using an adenovirus-recombinant vector has provided a safe route for inducing protection in animals against pandemic influenza in preclinical studies. The vaccine is non-replicating, tissue culture based and designed for intranasal delivery.
Detailed description
Objectives: The primary objective is to evaluate the safety of the AdhVN1203/04.H5 vaccine when administered intranasally in two doses with an interval of 28 days in healthy adults 19-49 years of age. The secondary objective is to evaluated the immunogenicity of the AdhVN1203/04.H5 vaccine at three different doses (10e8, 10e9 and 10e10 viral particles) when administered intranasally in two doses with an interval of 28 days in healthy adults 19-49 years of age.
Interventions
BIOLOGICALPandemic Influenza Vaccine
Undetermined
BIOLOGICALPlacebo
Sponsors
Altimmune, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
19 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy males and females in good general health, 19-49 years of age * Subjects must provide written consent * Willing to participate through study completion * Willing to undergo nasal washes and swabs and provide urine and blood samples per protocol for safety and immunogenicity analysis * Female of child-bearing age must have a negative urine pregnancy test and be stable on a reliable means of contraception. * Meet screening criteria for hematology, chemistry and urinalysis
Exclusion criteria
* Pregnant (or possibly pregnant) and lactating women * Any flu/cold symptoms and/or fever greater than 101 degrees in 3 days prior to study enrollment * Any intranasal steroid medication administered in the 10 days prior to study enrollment * History of chronic rhinitis or presence of pre-existing nasal septal defects, nasal polyps or other gross abnormalities * Any previous nasal cautery or significant surgery for nasal septal defects * Any regular past or current use of intranasal illicit drugs or history of intravenous illicit drug use * Asthma that is greater than mild in severity * Diagnosed active Hepatitis B or C * HIV positive at screening * Known or suspected malignancy, leukemia, or lymphoma * Immunosuppressed, altered or compromised immune status as a consequence of disease or treatment with systemic corticosteroids * Receipt of an influenza vaccine within the past 6 months * Receipt of any vaccine in the past 30 days * Receipt of any investigational drug in the past 30 days * Known Diabetes mellitus * History of anaphylaxis or angioedema * Hypertension that is not well controlled * Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgment of the investigator would serve to interfere or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a participants's ability to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the safety of a nasally administered adenovirus-vectored pandemic influenza vaccine in healthy human adults. | 56 day observations with 2 year follow-up |
Secondary
| Measure | Time frame |
|---|---|
| Determination of immunogenicity and correlates of protection based on HI titers in vaccinates | 28 days and 56 days post vaccination |
Countries
United States
Outcome results
None listed